Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Adjuvant therapy in RCC: harnessing prognostic information

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses value-based decision making in the adjuvant setting for patients with renal cell carcinoma (RCC), highlighting the importance of understanding which patients are more likely to respond to adjuvant treatment approaches by harnessing prognostic risk information. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.